Status: Full-time
Position Summary
The Internal Audit Manager leads audit activities at the Japan site, focusing on compliance with the U.S. Sarbanes-Oxley Act (SOX). Responsibilities include evaluating internal controls over financial reporting (ICFR), IT controls, and operational processes to support governance, risk management, and regulatory compliance.
Responsibilities
- Develop, improve the internal audit & control system to align with regulatory requirements under feasible cost
- Develop and execute annual audit plans, including US-SOX compliance audits
- Design and improve audit methodologies aligned with J-SOX where applicable
- Evaluate and document internal controls over financial reporting (ICFR)
- Conduct IT audits covering applications, infrastructure, and access controls
- Prepare audit reports and follow up on remediation plans
- Coordinate audit policies and reporting with Audit committees
- Liaise with external auditors
- Manage and mentor audit team members
- Support fraud risk assessments and investigations as needed
Qualifications
Required：
- Minimum 5 years of experience in internal or external audit
- Hands-on experience with US-SOX audits, especially ICFR
- High business-level English & Japanese proficiency. Mandarin speaker is strong plus.
- Strong analytical, problem-solving, and communication skills
Preferred：
- Experience in pharmaceutical, medical device, or manufacturing industries
- Certifications such as CIA, CPA (US), CISA
- Knowledge of ERP systems (e.g., SAP, Oracle NetSuite)
- IT audit or data analytics skills (e.g., ACL, Power BI)
- Audit experience in global organizations
Desired Skills and Attributes
- Ability to operate with a global mindset
- Self-driven and capable of leading teams
- Flexible and proactive in proposing improvements
- High ethical standards and objectivity
Top Skills
What We Do
Rakuten Medical, Inc. is a global clinical stage biotechnology company developing and commercializing precision, cell-targeting investigational therapies on its AlluminoxTM platform, which, in pre-clinical studies have been shown to induce rapid and selective cell killing and tumor necrosis. Outside of Japan, Alluminox therapies have not yet been approved as safe or effective by any regulatory authority. The company’s first drug developed on the Alluminox platform, ASP-1929, has received approval from the Japanese Ministry of Health, Labour, and Welfare, and is currently the subject of a global phase 3 clinical trial for recurrent head and neck cancer. Rakuten Medical is committed to its mission to conquer cancer and aims to realize a society where cancer patients can lead fulfilling lives. The company has locations in 5 countries, including the United States, where it is headquartered, Japan, the Netherlands, Taiwan, and Switzerland. For more information, visit www.rakuten-med.com.
